Current Report Filing (8-k)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

July 26, 2016

Date of Report (Date of earliest event reported)

 

Immune Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Florida		000-54933		59-3226705
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.

 

37 North Orange Ave, Suite 607, Orlando, FL		32801
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code 888-613-8802

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

[  ]	Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
[  ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 8.01. Other Events.

 

On July 26, 2016, the Company issued a press release in the form attached hereto as Exhibit 99.1 related to an informational shareholder meeting for Immune Therapeutics, Inc. to be held on August 17, 2016 at 10 a.m. at the Citrus Club located at 255 South Orange Ave, Suite 1800, Orlando, FL 32801.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits. The following exhibits are filed herewith.

 

Exhibit No.		Description
99.1		Press Release

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	IMMUNE THERAPEUTICS, INC.
Date: July 26, 2016	By:	/s/ Noreen Griffin
		Noreen Griffin, CEO